4-Methoxy-4-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-2-yl]tetrahydropyran

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-Methoxy-4-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-2-yl]tetrahydropyran
• 英文别名: 6-[5-(4-methoxyoxan-4-yl)thiophen-2-yl]sulfanyl-1-methyl-3,4-dihydroquinolin-2-one
• 化学式: C₂₀H₂₃NO₃S₂
• 分子量: 389.5
• InChiKey: KISROBRRFKHWAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  92.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-(5-bromothien-2-yl)-4-methoxytetrahydropyran 、 di-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl) disulfide 以to give 4-methoxy-4-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-2-yl]tetrahydropyran in 55% yield, m.p. 84°-86° C.的产率得到4-Methoxy-4-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-ylthio)thien-2-yl]tetrahydropyran
  参考文献：
  名称：

  Substituted-optionally hydrogenated isoquinoline compounds,

  摘要：

  本发明涉及公式I的杂环衍生物 ##STR1## 其中Ar.sup.1是可选取代的苯基，萘基或9-或10-成员的双环杂环基；A.sup.1是直接连接到X.sup.1或(1-3C)烷基链；X.sup.1是氧，硫，亚磺酰基，磺酰基或亚胺基；Ar.sup.2是可选取代的5-成员杂环基；R.sup.1是(1-4C)烷基，(3-4C)烯基或(3-4C)炔基；R.sup.2和R.sup.3共同形成公式--A.sup.2--X.sup.2--A.sup.3--的基团，其中A.sup.2和A.sup.3分别是(1-3C)烷基链，X.sup.2是氧，硫，亚磺酰基或磺酰基；或其药学上可接受的盐。本发明化合物是5-脂氧合酶酶的抑制剂。

  公开号：

  US05217978A1

文献信息

• Substituted-optionally hydrogenated isoquinoline compounds,
  申请人：Imperial Chemical Industries PLC

  公开号：US05217978A1

  公开（公告）日：1993-06-08

  The invention concerns a heterocyclene derivative of the formula I ##STR1## wherein Ar.sup.1 is optionally substituted phenyl, naphthyl or a 9- or 10-membered bicyclic heterocyclic moiety; A.sup.1 is a direct link to X.sup.1 or (1-3C)alkylene; X.sup.1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar.sup.2 is optionally substituted 5-membered heterocyclene moiety; R.sup.1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the carbon atom to which A.sup.2 and A.sup.3 are attached, defines a ring having 5 to 7 ring atoms, wherein each of A.sup.2 and A.sup.3 is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl or sulphonyl; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  本发明涉及公式I的杂环衍生物 ##STR1## 其中Ar.sup.1是可选取代的苯基，萘基或9-或10-成员的双环杂环基；A.sup.1是直接连接到X.sup.1或(1-3C)烷基链；X.sup.1是氧，硫，亚磺酰基，磺酰基或亚胺基；Ar.sup.2是可选取代的5-成员杂环基；R.sup.1是(1-4C)烷基，(3-4C)烯基或(3-4C)炔基；R.sup.2和R.sup.3共同形成公式--A.sup.2--X.sup.2--A.sup.3--的基团，其中A.sup.2和A.sup.3分别是(1-3C)烷基链，X.sup.2是氧，硫，亚磺酰基或磺酰基；或其药学上可接受的盐。本发明化合物是5-脂氧合酶酶的抑制剂。
• The use of lipoxygenase and cyclooxygenase inhibitors as synergistic agents
  申请人：ZENECA LIMITED

  公开号：EP0485111A2

  公开（公告）日：1992-05-13

  The invention relates to synergistic agents for the treatment of inflammatory or arthritic conditions which comprise one of a selected group of inhibitors of the enzyme 5-lipoxygenase in conjunction or admixture with an inhibitor of the enzyme cyclooxygenase. Conveniently the 5-lipoxygenase inhibitor is, for example, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl]phenoxy)methyl]-1-methyl-2-quinolone or 4-[5-fluoro-3-(4-methyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-7-ylthio)phenyl]-4-methoxytetrahydropyran and the cyclooxygenase inhibitor is selected from indomethacin, flurbiprofen and diclofenac. The invention also relates to a pharmaceutical composition containing said synergistic agent and to the use of said agent in the manufacture of a medicament for the synergistic treatment of inflammatory or arthritic disease.

  本发明涉及用于治疗炎症或关节炎的增效剂，该增效剂由一组选定的 5-脂氧合酶抑制剂中的一种与环氧合酶抑制剂结合或混合而成。例如，5-脂氧合酶抑制剂是 6-[(3-氟-5-[4-甲氧基-3,4,5,6-四氢-2H-吡喃-4-基]苯氧基)甲基]-1-甲基-2-喹啉酮或 4-[5-氟-3-(4-甲基-3-氧代-2、3-二氢-4H-1,4-苯并恶嗪-7-硫基)苯基]-4-甲氧基四氢吡喃，环氧化酶抑制剂选自吲哚美辛、氟比洛芬和双氯芬酸。本发明还涉及一种含有所述增效剂的药物组合物，以及使用所述增效剂制造协同治疗炎症或关节炎疾病的药物。
• Thiazole derivatives as lipoxygenase inhibitors
  申请人：ZENECA LIMITED

  公开号：EP0636624A1

  公开（公告）日：1995-02-01

  The invention concerns a thiazole derivative of the formula I wherein Q is 2-oxo-1,2,3,4-tetrahydroquinolin-6-yl or 2-oxo-1,2-dihydroquinolin-6-yl which bears on the nitrogen atom at the 1-position a (1-4C)alkyl substituent; X¹ is thio, sulphinyl or sulphonyl; Ar is thiazolediyl; R¹ is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R² and R³ together form a group of the formula -A²-X²-A³- which together with the carbon atom to which A² and A³ are attached define a ring having 5 or 6 ring atoms, wherein A² and A³, which may be the same or different, each is (1-3C)alkylene and X² is oxy, and which ring may bear one or two (1-4C)alkyl substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

  本发明涉及一种式 I 的噻唑衍生物 其中 Q 是 2-氧代-1,2,3,4-四氢喹啉-6-基或 2-氧代-1,2-二氢喹啉-6-基，其氮原子上 1 位有一个 (1-4C)烷基取代基； X¹ 为硫代、亚砜基或磺酰基； Ar 是噻唑二基； R¹ 是(1-4C)烷基、(3-4C)烯基或(3-4C)炔基；以及 R² 和 R³ 共同形成一个式 -A²-X²-A³- 的基团，该基团与 A² 和 A³ 所连接的碳原子一起定义了一个具有 5 或 6 个环原子的环，其中 A² 和 A³ 可以相同或不同，各自为 (1-3C) 亚烷基，X² 为氧基，该环可以带有一个或两个 (1-4C) 烷基取代基； 或其药学上可接受的盐； 它们的制备工艺；含有它们的药物组合物及其作为 5-脂氧合酶抑制剂的用途。
• Pyran derivatives as inhibitors of 5-lipoxygenase
  申请人：ZENECA LIMITED

  公开号：EP0462812B1

  公开（公告）日：1995-12-06
• 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors
  申请人：ZENECA LIMITED

  公开号：EP0623614B1

  公开（公告）日：1998-02-25